. . . . . . . . . . . . "approved"@en . . . . . . . "The electrophysiological effect of propafenone manifests itself in a reduction of upstroke velocity (Phase 0) of the monophasic action potential. In Purkinje fibers, and to a lesser extent myocardial fibers, propafenone reduces the fast inward current carried by sodium ions, which is responsible for the drugs antiarrhythmic actions. Diastolic excitability threshold is increased and effective refractory period prolonged. Propafenone reduces spontaneous automaticity and depresses triggered activity. At very high concentrations in vitro, propafenone can inhibit the slow inward current carried by calcium but this calcium antagonist effect probably does not contribute to antiarrhythmic efficacy."@en . . . "Nearly completely absorbed following oral administration (90%). Systemic bioavailability ranges from 5 to 50%, due to significant first-pass metabolism. This wide range in systemic bioavailability is related to two factors: presence of food (food increases bioavailability) and dosage (bioavailability is 3.4% for a 150-mg tablet compared to 10.6% for a 300-mg tablet)."@en . . . . . . . "97%"@en . . . . "* 252 L"@en . . " "@en . "An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. [PubChem]"@en . " "@en . . . . . . . . . . "Propafenona"@en . . . "Helmut Lietz, \"Preparation of propafenone.\" U.S. Patent US4474986, issued May, 1974."@en . "Used to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. Also used for the treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia."@en . . . . . . . . . "Symptoms of propafenone overdose (usually most severe within the first 3 hours) may include convulsions (rarely), heartbeat irregularities, low blood pressure, and sleepiness."@en . . . . . . . . . "Propafenonum"@en . . . "Always take at the same time in regard to meals."@en . . "2-10 hours"@en . . . . . . . "Grapefruit and grapefruit juice should be avoided throughout treatment. Grapefruit can increase serum levels of this product."@en . . "2-(2'-Hydroxy-3'-propylaminopropoxy)-omega-phenylpropiophenone"@en . "Humans and other mammals"@en . . "1-(2-(2-Hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone"@en . "Propafenone"@en . . . . . . . . . . . . . . "54063-53-5"@en . . . . . . . . . . . . "Approximately 50% of propafenone metabolites are excreted in the urine following administration of immediate release tablets. "@en . . . . .